| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2020NatCo..11.2319D |
| P356 | DOI | 10.1038/S41467-020-16128-5 |
| P932 | PMC publication ID | 7210950 |
| P698 | PubMed publication ID | 32385234 |
| P50 | author | Oliver Hantschel | Q30225123 |
| Dmitri Svergun | Q37375734 | ||
| Marco De Vivo | Q37843229 | ||
| Maria J Marcaida | Q48547074 | ||
| Florence Pojer | Q94563258 | ||
| Daniel P Duarte | Q94569344 | ||
| Sandrine Georgeon | Q94569347 | ||
| P2093 | author name string | Matteo Dal Peraro | |
| Alejandro Panjkovich | |||
| Hak-Sung Kim | |||
| Yoo-Kyoung Sohn | |||
| Giuseppina La Sala | |||
| Sukyo Jeong | |||
| Allan J Lamontanara | |||
| Tim Kükenshöner | |||
| P2860 | cites work | Polymorphic transitions in single crystals: A new molecular dynamics method | Q97681190 |
| Solution structure and phosphopeptide binding of the SH2 domain from the human Bruton's tyrosine kinase | Q24302562 | ||
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation | Q24648477 | ||
| Structure of the carboxyl-terminal Src kinase, Csk | Q27638251 | ||
| A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain | Q27660385 | ||
| Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis | Q27675049 | ||
| Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering | Q27677231 | ||
| Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains | Q27679810 | ||
| Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity | Q27698513 | ||
| Regulation of Btk function by a major autophosphorylation site within the SH3 domain | Q28278818 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Canonical sampling through velocity rescaling | Q29616131 | ||
| CRYSOL– a Program to Evaluate X-ray Solution Scattering of Biological Macromolecules from Atomic Coordinates | Q29642130 | ||
| Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate | Q30009224 | ||
| SH2-dependent autophosphorylation within the Tec family kinase Itk. | Q30157228 | ||
| A remote substrate docking mechanism for the tec family tyrosine kinases | Q30157996 | ||
| Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering. | Q30164519 | ||
| Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA). | Q30168594 | ||
| Kinetics of protein-ligand unbinding via smoothed potential molecular dynamics simulations | Q30655357 | ||
| SASpy: a PyMOL plugin for manipulation and refinement of hybrid models against small angle X-ray scattering data | Q31092420 | ||
| Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies | Q33637065 | ||
| Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | Q34001339 | ||
| Regulation of the c-Abl and Bcr-Abl tyrosine kinases | Q35621355 | ||
| The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib | Q35925610 | ||
| BTKbase: the mutation database for X-linked agammaglobulinemia. | Q36592292 | ||
| ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. | Q36766916 | ||
| Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface | Q36884733 | ||
| Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 | ||
| Accurate assessment of mass, models and resolution by small-angle scattering | Q37021738 | ||
| Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. | Q38068249 | ||
| Targeting pathological B cell receptor signalling in lymphoid malignancies | Q38085501 | ||
| Unexpected off-targets and paradoxical pathway activation by kinase inhibitors | Q38296973 | ||
| ATSAS 2.8: a comprehensive data analysis suite for small-angle scattering from macromolecular solutions | Q38624857 | ||
| AGC kinases, mechanisms of regulation and innovative drug development. | Q39357961 | ||
| DAMMIF, a program for rapid ab-initio shape determination in small-angle scattering | Q39388340 | ||
| Deciphering conformational transitions of proteins by small angle X-ray scattering and normal mode analysis | Q40270412 | ||
| A myristoyl/phosphotyrosine switch regulates c-Abl | Q40661872 | ||
| Achieving a Graded Immune Response: BTK Adopts a Range of Active/Inactive Conformations Dictated by Multiple Interdomain Contacts | Q47862459 | ||
| BiKi Life Sciences: A New Suite for Molecular Dynamics and Related Methods in Drug Discovery. | Q48233999 | ||
| Role of Bruton's tyrosine kinase in B cells and malignancies | Q49888075 | ||
| The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. | Q51090690 | ||
| A Convergence-Based Framework for Cancer Drug Resistance. | Q53682041 | ||
| Consensus Bayesian assessment of protein molecular mass from solution X-ray scattering data. | Q55032893 | ||
| Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems | Q56750591 | ||
| PRIMUS: a Windows PC-based system for small-angle scattering data analysis | Q57091059 | ||
| Six X-Linked Agammaglobulinemia-Causing Missense Mutations in the Src Homology 2 Domain of Bruton's Tyrosine Kinase: Phosphotyrosine-Binding and Circular Dichroism Analysis | Q57269819 | ||
| The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases | Q57752422 | ||
| Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants | Q90205308 | ||
| Bruton tyrosine kinase degradation as a therapeutic strategy for cancer | Q90461959 | ||
| Targeted Protein Degradation through Cytosolic Delivery of Monobody Binders Using Bacterial Toxins | Q91538610 | ||
| Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase | Q92415144 | ||
| Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study | Q93051331 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 2319 | |
| P577 | publication date | 2020-05-08 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms | |
| P478 | volume | 11 |
Search more.